EFFICACY OF PIOGLITAZONE AS AN ADD ON DRUG WITH INSULIN, GLIBENCLAMIDE AND METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS
|
|
- Milton Cox
- 8 years ago
- Views:
Transcription
1 Diabetes Clinic and Research Centre, Shreeniwas, Opposite Dhantoli Park, Nagpur, India Phone: Fax: sharad@nagpur.dot.net.in Professional Paper EFFICACY OF PIOGLITAZONE AS AN ADD ON DRUG WITH INSULIN, GLIBENCLAMIDE AND METFORMIN IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES MELLITUS Sharad P. Pendsey, V. P. Dhanvijay, P. P. Joshi Key words: peroxisome proliferator-activated receptor -γ (PPAR-γ), pioglitazone, thiazolidinedione, glitazone, drug therapy, type 2 diabetes mellitus SUMMARY The aim of the study was to evaluate the clinical efficacy and safety of pioglitazone in patients with poorly controlled type 2 diabetes mellitus (DM), despite treatment with insulin and a combination of glibenclamide and metformin. Fifty-seven patients with type 2 DM, mean age years and mean body mass index (BMI) kg/m 2, were enrolled in this unicenter open label trial. They were given pioglitazone 30 mg/day in addition to previous treatment with insulin ( 30 units a day), glibenclamide (10 mg a day) and metformin (1000 mg a day) for a period of six months. Pioglitazone 30 mg/day, when added to insulin and the combination of glibenclamide and metformin, significantly decreased hemoglobin A 1c at six months from a mean of 8.15%±0.24 to a mean of 7.17%±0.42 (p<0.0001) and fasting plasma glucose at six months from a mean of 209.3±32.43 mg/dl to ±36.94 mg/dl (p<0.0001). Pioglitazone was well tolerated throughout the study period. Pioglitazone was found to improve glycemic control, when given as a fourth drug (quadruple drug therapy) in addition to insulin and the combination of glibenclamide and metformin in patients with type 2 DM. Foot edema and weight gain were common side effects. In a significant number of patients, insulin therapy could be stopped, and in the rest the dose of insulin and glibenclamide could be reduced. INTRODUCTION Chronic hyperglycemia in patients with type 2 diabetes mellitus (DM) occurs because of resistance to the action of insulin and decreasing insulin secretion. Insulin resistance is a prominant feature, if not the primary defect. In some of these patients, insulinstimulated uptake of glucose is decreased by 60% to 80% (1). Patients with type 2 diabetes are often treated according to a stepped progression, starting with a regimen of nutrition and exercise, and progressing to sulphonylurea, metformin and acarbose alone or in combination. These therapies are often ineffective. The longer the diabetes has been present, the more likely the patients are to require insulin to control their hyperglycemia (2,3). Despite insulin treatment, often in high doses, hyperglycemia in these patients is not well controlled (2). In UKPDS (4), glycemic control deteriorated continuously, even in intensively treated patients with type 2 diabetes. In order to reduce insulin dose in type 2 diabetes, various studies have been carried out using combination therapies with insulin and sulphonylureas (5,6), insulin and metformin (7,8) and insulin in combination with sulphonylureas and metformin (9-11). The insulin sparing effect of the two drugs, sulphonylurea and metformin, in addition to insulin was 62%, i.e., 1.5- to 2.0-fold effect achieved by the regimens combining either metformin alone or sulphonylureas alone with insulin (9-13). 51
2 Thiazolidinediones, a new class of oral antidiabetic agents, reduce hyperglycemia by decreasing insulin resistance in peripheral tissues (1,14). They act by binding to the peroxisome proliferator-activated receptor-γ (PPAR-γ) (15) and altering expression of the component that influences the insulin signaling and glucose transport systems (1). Glitazones, when added to previous insulin treatment, have improved glycemic control in patients with type 2 diabetes (16-18). In India, the experience with thiazolidinediones is limited, as troglitazone was never introduced for clinical use and rosiglitazone and pioglitazone have been introduced for the last two years. The current trial was conducted to determine whether the addition of a glitazone, pioglitazone, could improve the glycemic control in patients with uncontrolled type 2 DM despite therapy with insulin combined with glibenclamide and metformin. SUBJECTS AND METHODS The efficacy of pioglitazone was assessed in a unicenter open label trial. Indian men and women aged years, body mass index (BMI) kg/m 2, with stable body weight and type 2 DM for at least over one year, high hemoglobin A 1c (HbA 1c ) levels of 8% and fasting plasma glucose of 180 mg/dl were included. Patients who were poorly controlled despite combination treatment with glibenclamide (10 mg a day) and metformin (1000 mg a day) along with twice a day insulin therapy ( 30 units a day) for over three months were eligible for recruitment. Patients with clinically significant renal disease, New York Heart Association (NYHA) class III/IV coronary insufficiency or congestive heart failure, symptomatic diabetic neuropathy, past or present hepatic disease, ketonuria, active infections, and women of child bearing potential were excluded. All subjects signed an informed consent before participation in the study. The protocol was approved by the institution ethics committee. The study was conducted in accordance with the Declaration of Helsinki. Patients who met the inclusion criteria were invited to participate in the study. In the beginning, a complete history and physical examination were carried out. A twelve lead electrocardiogram (ECG) was recorded at baseline and after six months. Clinical chemistry was performed on fasting samples on a Techinicon Ames RA-50 chemistry autoanalyzer with strict quality control. Fasting plasma glucose was estimated at baseline and each monthly visit, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were estimated at baseline, one month, two months and six months, and HbA 1c was estimated at baseline and three and six months. Hematologic parameters and serum creatinine were measured at baseline and six months. Self monitoring of blood glucose levels was encouraged. Patients were given a fixed dose of pioglitazone 30 mg once a day for six months, in addition to insulin, glibenclamide and metformin. During the study period, no increase in the dosage of insulin, glibenclamide and metformin were allowed. However, a decrease in the dose of insulin and glibenclamide, if required, were made when patients had fasting plasma glucose concentration below 90 mg/dl at one office visit, a concentration of 90 to 110 mg/dl on two consecutive office visits, or a concentration of 100 mg/dl on two consecutive days during self monitoring at home (16). Investigations like lipid parameters and C-peptide were not performed due to financial constraints. There was no control group with placebo therapy as the ethics committee did not feel it rational to expose the control group to hyperglycemia for six months. At the end of the study, patients were classified as responders if fasting plasma glucose was 110 mg/dl and HbA 1c 7.0%, and the rest were nonresponders. Statistical analysis Statistical analysis was performed using Minitab Release 11.2, 1996 and Stata 7.0 statistical packages. Student s t-test was used to compare continuous variables (paired t-test for paired data and two-sample t-test for unpaired data). The χ 2 -test was used to compare categorical variables. Multiple logistic regression analysis was performed to determine the variables significantly associated with responders. The 95% confidence interval (CI) and odds ratio were computed whenever applicable. The analysis of efficacy was performed according to the intention-totreat method and included all patients who received at least one dose of pioglitazone and had at least one follow up visit. The last observation for patients was carried forward to impute missing values. The safety analysis also included all patients. Data are presented as mean ± SD. A p value <0.05 was considered statistically significant. 52
3 RESULTS Of the 57 subjects recruited, 52 subjects completed the study. Among the patients excluded, three were lost to follow up, one withdrew because of severe foot edema, and in one patient pioglitazone was withdrawn as he developed jaundice. Clinical characteristics of the 57 subjects at recruitment are summarized in Table 1. There was a significant decrease in HbA 1c at six months from a mean of 8.15% ± 0.24 to 7.17% ± 0.42 (p<0.0001) (Fig. 1); 30 (52.63%) patients achieved HbA 1c 7%. There was a significant decrease in fasting plasma glucose at six months from a mean of mg/dl ± to mg/dl ± (p<0.0001), beginning at one month and reaching maximal effects at six months (Fig. 2); 24 (42.10%) patients achieved fasting plasma glucose of 110 mg/dl. There were 21 (36.84%) patients who could be classified as responders, who achieved both fasting plasma glucose 110 mg/dl and HbA 1c 7%. There was a significant increase in the mean body weight by 2.43 kg (p<0.0001) and BMI by 0.64 kg/m 2 (p<0.0005). There was no significant change in WHR. Pioglitazone was well tolerated throughout the study. There was a slight drop in hemoglobin and hematocrit values at six months but the fall was not statistically significant. There were no clinically significant changes in ECG recordings. Transient elevations greater than 1.5 times the upper limit of normal AST and ALT levels were not observed in any but one study patient. Nineteen (33.33%) patients experienced foot edema. No adverse changes in renal function were evident during the study. Symptoms associated with hypoglycemia were reported by 13 (22.80%) patients. Most patients who reported hypoglycemia experienced one episode. In two cases hypoglycemia was severe enough to require hospitalization with third party intervention, and there was a documented plasma glucose level <35 mg/dl. The mean dose of insulin decreased during the study from ± 9.93 units per day to 20.0 ± 9.6 units/day at six months (p<0.0001). The frequency of insulin injections decreased from a mean of 2.05 ± 0.22/day to 1.18 ± 1.05/day (p<0.0001). In 24 (42.10%) patients insulin had to be totally stopped. The mean dose of glibenclamide significantly decreased from ±1.29 to 9.47±1.69 mg/day (p<0.0005). In six (10.52%) patients the dose of glibenclamide decreased Table 1. Baseline characteristics (intention-to-treat population) N 57 Age (yrs) ± 7.81 Sex: Male Female Diabetes duration (yrs) 9.75 ± 5.47 BMI (kg/m 2 ) ± 4.15 WHR 0.92 ± 0.08 Body weight (kg) ± Fasting plasma glucose (mg/dl) ± HbA 1c (%) 8.15 ± 0.24 Data are mean ± SD Figure 1. Decrease in mean HbA 1c (%) (mean ± SEM) Mean HbA 1c (%) months Figure 2. Decrease in mean fasting plasma glucose (mean ± SEM) Mean fasting plasma glucose (mg/dl) months 53
4 by 50%. There was no change in the dose of metformin during the study. DISCUSSION In the present study, the study sample was significantly hyperglycemic, as evident by the mean baseline HbA 1c level of 8.15% and fasting plasma glucose level of mg/dl. A significant number of patients (n=30; 52.63%) achieved HbA 1c level of 7%. Similarly, 24 (42.1%) patients achieved a fasting plasma glucose of 110 mg/dl. The 6-month duration of the study was intended to provide a sufficient exposure to demonstrate the maximal therapeutic effect, as assessed by reduction in the HbA 1c and fasting plasma glucose levels. Our study has provided evidence supporting the use of pioglitazone as an add on drug in type 2 diabetes patients with inadequate glycemic control despite the treatment with insulin and combination doses of glibenclamide and metformin. The quadruple drug therapy used in the study demonstrated early and sustained reductions in fasting glucose levels, followed more slowly by similar reductions in HbA 1c levels. A previous study using troglitazone as a third drug after sulphonylurea and metformin showed similar glycemic efficacy (19). In this study, ten (22.8%) patients treated with pioglitazone reported symptomatic hypoglycemia. Two patients had neuroglycopenia and required emergency treatment. The incidence of reported hypoglycemia was evenly distributed over the entire 6-month study period, suggesting that hypoglycemic symptoms are not directly associated with the initiation of pioglitazone therapy. Pioglitazone therapy can lead to hypoglycemic episodes when used in combination with insulin or insulin secretagogue. Concurrent decrease in insulin doses and insulin secretagogue therapy is warranted when patients experience frank hypoglycemia or sustained reduction in plasma glucose levels. In the present study there was a significant reduction in the insulin requirement as well as in the frequency of insulin injections, and a decrease in the mean dose of glibenclamide. Insulin therapy had to be totally stopped in 24 (42.10%) patients, and the addition of pioglitazone led to insulin sparing by 56.32%. We also tried to assess the responders and their relationship with other clinical characteristics such as age, sex, duration of diabetes, body weight, BMI, WHR, baseline fasting plasma glucose and HbA 1c. However, we did not find any significant correlation of these characteristics with responders except for a significant association of responders with female sex (p<0.005). The excess of adipose tissue in females could be the possible explanation. Similar findings have been reported by Patel et al. (20). They also found that patients with BMI >27 kg/m 2 responded better than those with BMI <27 kg/m 2. The significant weight gain observed in the present study may be attributed to increased adipocyte differentiation (21,22), fluid retention (21,23) or increased appetite (24). Improved glycemic control, despite weight gain, has been reported with thiazolidinediones (20,25-27). Thiazolidinediones associated weight gain is due to increased subcutaneous fat and a simultaneous decrease in visceral abdominal fat, as reported by Kelly et al. (28). In the present study, weight gain in 10 patients was 5 kg, maximum 13 kg in two patients. In 19 patients there was no weight gain. There was no weight loss in any of the study patients during the study period. Small decreases in hemoglobin and hematocrit levels have been described with pioglitazone therapy, which may relate to plasma volume expansion derived from fluid retention and hemodilution (29). However, we did not find any statistically significant decrease in hemoglobin or hematocrit at six months from baseline. Foot edema was found to be a common side effect of thiazolidinedione therapy and is attributed to fluid retention (21,23). In the present study, 19 (33.33%) patients experienced foot edema. One female patient withdrew from the study because of disturbing pedal edema. We did not find any significant hepatotoxicity with pioglitazone therapy, however, one patient developed jaundice within one month of starting pioglitazone and the drug had to be withdrawn. This 40-year-old male was further investigated, his sonography was normal and hepatitis markers for hepatitis A, B, C were negative. His hepatitis E IgM value was significantly raised. The patient made an uneventful recovery in two months, with return of serum bilirubin, alkaline phosphatase and ALT, AST values to normal. It was thought to be a case of viral hepatitis (HEV), a common infection in India (30,31), rather than a pioglitazone induced hepatitis. Yet, the challenge dose of pioglitazone was not given. Patients with type 2 DM are often treated according to a stepped progression, starting with a regimen of nutrition counseling and exercise, and progressing to 54
5 monotherapy with a sulphonylurea, metformin, or acarbose. As hyperglycemia worsens, combinations of oral agents are often required. When a combination of a sulphonylurea and metformin cannot achieve the treatment goals, insulin injections need to be initiated (32,33). However, most patients with type 2 DM who are treated with insulin remain uncontrolled despite the increase in insulin doses (2). Our study showed that pioglitazone was effective and well tolerated when used as a fourth drug with sulphonylurea (glibenclamide), metformin and insulin. The addition of pioglitazone reduced the requirement of insulin and glibenclamide. As the result, a proportion of such patients treated with quadruple drug therapy were able to reach target HbA 1c 7.0% and fasting plasma glucose levels 110 mg/dl. Insulin therapy had to be discontinued in 24 (42.10%) patients, and in the rest the insulin dosage was significantly reduced. Previous studies have shown that thiazolidinediones, used as monotherapy (26,34) or in combination with either sulphonylureas (35), metformin (36) or insulin (17-19), improve glycemic control in type 2 DM. However, in all these clinical situations, less expensive, safer and more effective alternatives are available. Although in this short, 6-month trial we found pioglitazone to be a safe drug, its longterm consequences are not known (37). In contrast, we have decades of experience with the extensive use of sulphonylureas and metformin. It is therefore rational to use thiazolidinediones either as a third drug for type 2 DM, after sulphonylurea and metformin, or a fourth drug in patients on insulin and combination of sulphonylurea and metformin, rather than making it the first option drug in therapy of type 2 DM. It was earlier thought that it is indeed rather illogical to introduce thiazolidinediones in later stages of the clinical course of type 2 DM, when there is a significant β-cell dysfunction (38). It has therefore been suggested that these agents might be tried much earlier in the clinical course of type 2 DM, perhaps in combination with metformin (39). Our study has shown that pioglitazone is effective even in later stages of the clinical course of type 2 DM and can be an add on drug for uncontrolled type 2 DM, administered along with insulin and a combination of sulphonylurea and metformin. CONCLUSION Our study has shown that pioglitazone is effective in improving the glycemic control when added to a combination of insulin, glibenclamide and metformin in type 2 DM. In a significant number of patients, insulin therapy could be stopped and in the rest the dosage of insulin and glibenclamide could be reduced. Pioglitazone is a relatively safe drug, but foot edema and weight gain are of great concern to both the patient and the treating physician. Pioglitazone is a valuable addition to the currently available oral antidiabetic agents. Acknowledgment: This work was in part supported by a grant from the charitable organization Dream Trust, Nagpur, India. REFERENCES 1. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996;45: Klein R, Klein BE, Moss SE, Cruickshanks KJ. The medical management of hyperglycemia over a 10- year period in people with diabetes. Diabetes Care 1996;19: Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16: U. K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115: Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination of sulfonylurea and insulin therapy useful in NIDDM patients? Diabetes Care 1992;15:
6 7. Relimpio R, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled type 2 diabetes mellitus: an open-label randomized trial. Diabet Med 1998;15: Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21: Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130: Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1992;327: Chow C-C, Tsang LWW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18: Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone: Glimepiride Combination Group. Diabetes Care 1998; 21: Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP, Nieuwenhuijzen KA. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19: Smith SA, Cawthorne MA, Coyle PJ, et al. BRL 49653C normalizes glycemic control in Zucker fatty fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin (Abstract). Diabetologia 1993;36 (Suppl 1):A Young PW, Buckle DR, Cantello BCC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatoractivated receptor γ.? J Pharmacol Exp Ther 1998;284: Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus: Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998;338: Rubin C, Egan J, Schneider R, Pioglitazone 014 Study Group. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes (Abstract). Diabetes 1999;48:A Raskin P, Dole JF, Rappaport EB. Rosiglitazone (RSG) improves glycemic control in poorly controlled, insulin-treated type 2 diabetes (Abstract). Diabetes 1999;48:A Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitecomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicentric, randomized, double blind, placebocontrolled trial. Ann Intern Med 2001;134: Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a twelve week randomized, placebo-controlled study. Diab Obes Metab 1999;1: Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16: Hallakau S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rats. Diabetes 1997;46: Young MM, Squassante L, Wemer J, Van Marie SP, Dogterom P, Johnkman JH. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol 1999;55: Shimizu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998;21: Seidell JC, Hautvart JG, Deurenberg P. Overweight: fat distribution and health risks. Infusionstherapie 1989;16: Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22:
7 27. Evans DI, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women. Metabolism 1984;33: Kelly IE, Walsh K, Han TS, Lean MEJ. Effect of thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22: Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction. Diabetes 1999;48 (Suppl 1):A Ray R, Aggarwal R, Salunke PN, et al. Hepatitis E virus genome in stools of hepatitis patients during large epidemic in North India. Lancet 1991;338: Khuroo MS. Study of an epidemic of non-a, non-b hepatitis: possibility of another human hepatitis virus distinct from post-transfusion non-a, non-b type. Ann J Med 1980;68: American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999;22 (Suppl 1):S32-S Meltzer S, Leiter L, Daneman D, et al Clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association CMAJ 1998;159 (Suppl 8):S1-S Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, for the Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24: Hortan ES, Whitehouse R, Ghazzi MN, Venable TC, Whitcomb RW, the Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998;21: Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes. JAMA 2000;283:
NCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationInterventions for improving glycemic control in type 2 diabetic patients
Interventions for improving glycemic control in type 2 diabetic patients Evgenia Vlachou 1, Zambia Vardaki 2, Urania Govina 1, Anna Kavga-Paltoglou 3, Vassiliki Kutsopoulou-Sofikiti 1, Martha Kelesi-Stavropoulou
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationTreating dual defects in diabetes: Insulin resistance and insulin secretion
Treating dual defects in diabetes: Insulin resistance and insulin secretion Nancy J.V. Bohannon, MD Am J Health-Syst Pharm. 2002; 59(Suppl 9):S9-13 ABSTRACT: The therapeutic goals in patients with type
More informationTuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationCOST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL
Malaysian Journal of Pharmaceutical Sciences, Vol. 5, No. 1, 19 23 (2007) COST ANALYSIS OF ANTIDIABETIC DRUGS FOR DIABETES MELLITUS OUTPATIENT IN KODYA YOGYAKARTA HOSPITAL TRI MURTI ANDAYANI* AND IKE IMANINGSIH
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationThe U.K. Prospective Diabetes Study
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Comparison of two treatment algorithms using insulin glargine
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationSummary ID# 13614. Clinical Study Summary: Study F3Z-JE-PV06
CT Registry ID# Page 1 Summary ID# 13614 Clinical Study Summary: Study F3Z-JE-PV06 INSIGHTS; INSulin-changing study Intending to Gain patients insights into insulin treatment with patient-reported Health
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationHumulin (LY041001) Page 1 of 1
(LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or
More informationThe Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies
CLINICAL DIABETES VOL. 18 NO. 2 Spring 2000 PRACTICAL POINTERS The Natural History of Type 2 Diabetes: Practical Points to Consider in Developing Prevention and Treatment Strategies Barbara A. Ramlo-Halsted,
More informationA prospective study on drug utilization pattern of anti-diabetic drugs in rural areas of Islampur, India
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):33-37 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationPractical Applications of Insulin Pump Therapy in Type 2 Diabetes
Practical Applications of Insulin Pump Therapy in Type 2 Diabetes Wendy Lane, MD For a CME/CEU version of this article please go to www.namcp.org/cmeonline.htm, and then click the activity title. Summary
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationEffect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
More informationImproving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
More informationUpdates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO. Managing Complicated Diabetes
dates for your practice March, 2013. Vol 2, Issue 14 TLALELETSO Managing Complicated Diabetes Diabetes is increasingly common Managing diabetes and working as part of a multidisciplinary team is essential
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationThe goal for glycemic control in current
Original Research N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Starting insulin in type 2 diabetes: Continue oral hypoglycemic agents? A randomized trial in primary care Alex N. Goudswaard,
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationAdherence to insulin therapy at a tertiary care diabetes center in South India
Original Article: Adherence to insulin therapy at a tertiary care diabetes center in South India M.S. Raut, J. Balasubramanian, R.M. Anjana, R Unnikrishnan, *V. Mohan Abstract To assess patient adherence
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationNONINSULIN-DEPENDENT diabetes mellitus
0021-972X/97/$03.00/0 Vol. 82, No. 8 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1997 by The Endocrine Society An Overnight Insulin Infusion Algorithm Provides Morning
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationCHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications
CHAPTER V DISCUSSION Background Diabetes mellitus is a chronic condition but people with diabetes can lead a normal life provided they keep their diabetes under control. Life style modifications (LSM)
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationComparison of the glycemic control of insulin and triple oral therapy in type 2 diabetes mellitus
Journal of Diabetes and Endocrinology Vol. 1(2), pp. 13-18, April 2010 Available online at http://www.academicjournals.org/jde ISSN 2141-2685 2010 Academic Journals Full Length Research Paper Comparison
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes
DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationInsulin therapy in type 2 diabetes
Med Clin N Am 88 (2004) 865 895 Insulin therapy in type 2 diabetes Trent Davis, MD, Steven V. Edelman, MD* Section of Diabetes/Metabolism, Veterans Affairs San Diego HealthCare System, 3350 La Jolla Village
More informationGlycemic Control of Type 2 Diabetes Mellitus
Bahrain Medical Bulletin, Vol. 28, No. 3, September 2006 Glycemic Control of Type 2 Diabetes Mellitus Majeda Fikree* Baderuldeen Hanafi** Zahra Ali Hussain** Emad M Masuadi*** Objective: To determine the
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationUse of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians
Original Article Use of Glimepiride and Insulin Sensitizers in the Treatment of Type 2 Diabetes A Study in Indians A Ramachandran, C Snehalatha, J Salini, V Vijay Abstract Aim : Short-term efficacy of
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationHow To Determine The Prevalence Of Microalbuminuria
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
More informationCriteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of
More informationUtilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Utilization of Oral Hypoglycemic Agents in a Drug-Insured U.S. Population STEPHEN J. BOCCUZZI, PHD 1 JENIFER WOGEN, MS 1
More informationDiabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO
Diabetes and Obesity in Children Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO Diabetes and Obesity in Children What is Diabetes? How are Diabetes and Obesity
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationWilliam W Quick, MD, FACP, FACE September 20, 2013 Former Safety Officer for Parke-Davis
William W Quick, MD, FACP, FACE September 20, 2013 Former Safety Officer for Parke-Davis All slides in this presentation have been copyrighted and can not be used without the presenter s permission Rezulin:
More informationMedical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10, 01/11, 01/12
Continuous or Intermittent Monitoring of Glucose in Interstitial (10120) Medical Benefit Effective Date: 04/01/11 Next Review Date: 01/13 Preauthorization* Yes Review Dates: 07/07, 07/08, 07/09, 01/10,
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationClinical Medicine: Therapeutics. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. N. Papanas and E. Maltezos
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationNancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background
Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationSYNOPSIS. Risperidone: Clinical Study Report CR003274
SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:
More informationJill Malcolm, Karen Moir
Evaluation of Fife- DICE: Type 2 diabetes insulin conversion Article points 1. Fife-DICE is an insulin conversion group education programme. 2. People with greater than 7.5% on maximum oral therapy are
More informationInsulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationlinagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd
linagliptin, 5mg film-coated tablet (Trajenta ) SMC No. (746/11) Boehringer Ingelheim / Eli Lilly and Company Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of
More informationUsing a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes
Special Series: AAFP Award-winning Research Papers Vol. 31, No. 5 331 Using a Flow Sheet to Improve Performance in Treatment of Elderly Patients With Type 2 Diabetes Gary Ruoff, MD; Lynn S. Gray, MD, MPH
More informationDIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE
DIABETES AND INSULIN RESISTANCE KARI KOHRS RD LDN CDE UICMC NUTRITION & WELLNESS CENTER DIABETES PREVALANCE Third leading cause of death-- United States 18 million diagnosed Growing at the rate of 3 new
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationThe Influence of Infant Health on Adult Chronic Disease
The Influence of Infant Health on Adult Chronic Disease Womb to Tomb Dr Clare MacVicar Introduction Many diseases in adulthood are related to growth patterns during early life Maternal nutrition important
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Incretin Mimetic/Enhancer Hypoglycemics (formerly referred to as Other Hypoglycemics) A. Thresholds for Prior Authorization All prescriptions
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More information